Clinical Trials Logo

Maintenance clinical trials

View clinical trials related to Maintenance.

Filter by:
  • None
  • Page 1

NCT ID: NCT05477797 Recruiting - Overall Survival Clinical Trials

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Start date: February 16, 2023
Phase: N/A
Study type: Interventional

Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.

NCT ID: NCT04539210 Recruiting - Clinical trials for Patient Satisfaction

Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework Versus Cast One, Patient Satisfaction Assessment.

Start date: September 2020
Phase: N/A
Study type: Interventional

In this study the investigators are going to compare the effect of electric welded metal frame work and cast frame work on patient satisfaction and maintenance of the final prosthesis.

NCT ID: NCT03983759 Recruiting - Clinical trials for Small Cell Lung Cancer

Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

Start date: June 20, 2019
Phase: Phase 2
Study type: Interventional

Small cell lung cancer is a highly aggressive malignancy. Currently, there is no effective regimen for patients after the progression offirst-line chemotherapy. The prognosis of patients with extensive disease is very poor, and the improved therapeutic efficacy is urgently needed. Most patients with small cell lung cancer have a long history of smoking, and the tumor mutation burden is relatively high, which provides potential for immunological checkpoint inhibitors represented by PD-1 antibodies. A number of studies have shown that chemotherapy combined with adoptive cellular immunotherapy could prolong the survival of patients. This study is a clinical study to explore the efficacy and safety of maintenance therapy with sintilimab after 4-6 cycles of first-line chemotherapy combined with adoptive cellular immunotherapy in patients with advanced small cell lung cancer.